Last reviewed · How we verify
The Effect of Aliskiren on Proteinuria in Chronic Nondiabetic Kidney Disease: a Double Blind Cross-over Randomized Controlled Trial (ALIPRES)
To evaluate the proteinuria lowering efficacy as well as tolerability and safety of the renin inhibitor aliskiren compared with that of placebo and angiotensin converting enzyme inhibitor perindopril in patients with non-diabetic chronic renal disease.
Details
| Lead sponsor | Medical University of Gdansk |
|---|---|
| Phase | Phase 4 |
| Status | COMPLETED |
| Enrolment | 16 |
| Start date | 2009-03 |
| Completion | 2010-09 |
Conditions
- Chronic Kidney Disease
- Proteinuria
- Blood Pressure
Interventions
- Aliskiren, Perindopril
Primary outcomes
- Investigate the antiproteinuric effect of adding aldosterone antagonist, spironolactone to the combination therapy with angiotensin converting enzyme inhibitor and AT-1 receptor blocker in maximal recommended doses. reduction of proteinuria — march 2014 - april 2014
Countries
Poland